Billiontoone, Inc. (NASDAQ:BLLN) Receives Average Rating of “Moderate Buy” from Analysts

Billiontoone, Inc. (NASDAQ:BLLN) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $138.6667.

A number of brokerages have recently weighed in on BLLN. Piper Sandler began coverage on shares of Billiontoone in a report on Monday. They set an “overweight” rating and a $150.00 price target for the company. Stifel Nicolaus started coverage on Billiontoone in a research note on Monday. They set a “buy” rating and a $145.00 target price for the company. Wall Street Zen raised Billiontoone to a “hold” rating in a report on Saturday, November 15th. JPMorgan Chase & Co. assumed coverage on Billiontoone in a report on Monday, December 1st. They set an “overweight” rating and a $150.00 price target for the company. Finally, Wells Fargo & Company started coverage on Billiontoone in a research report on Monday. They set an “equal weight” rating and a $110.00 price objective for the company.

Billiontoone Trading Up 7.3%

BLLN opened at $111.64 on Monday. Billiontoone has a twelve month low of $88.00 and a twelve month high of $138.70.

Billiontoone Company Profile

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.